Immunohistochemical Demonstration of Thymidylate Synthase (Ts), P53 Protein and BCl-XL Protein in Colorectal Cancer with Preoperative Peroral Chemotherapy: Ts as Marker of Unresponsiveness To 5-Fluorouracil

Annals of Cancer Research and Therapy

Volumn 11, Issue 42371, 2003, Pages 73-94

  Kamoshida, Shingo ^a   Matsuyama, Atsuji ^a   Shimomura, Ryoichi ^a   Tsutsumi, Yutaka ^a   Matsuoka, Hiroshi ^a   Maruta, Morito ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Bc1 Xl protein; cancer; chemoresistance; colorectal malignancies; grading of colorectal tumors; immunoperoxidase staining; inhibition of apoptosis; p53 protein; selection of patients; thymidylate synthase (TS)

Indexed keywords

BIOCHEMICAL MARKER; FLOXURIDINE; FLUOROURACIL DERIVATIVE; PEROXIDASE; PROTEIN BCL XL; PROTEIN P53; THYMIDYLATE SYNTHASE; TUMOR ANTIGEN; UFT;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; COLON BIOPSY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MALE; PATIENT SELECTION; PREDICTION; PREOPERATIVE CARE; PROTEIN EXPRESSION; RECTUM BIOPSY;

EID: 4344696433     PISSN: 13446835     EISSN: None     Source Type: Journal    
DOI: 10.4993/acrt1992.11.73     Document Type: Article

References (43)

1. Backus, H.H., Dukers, D.F., van Groeningen, C.J., Vos, W., Bloemena, E., Wouters, D., van Riel, J.M., Smid, K., Giaccone, G, Pinedo, H.M. and Peters, GJ. (2001). 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann. Oncol. 12: 209-216.
2. Benhattar, J., Cerottini, J-P, Saraga, E., Metthez, G. and Givel, J-C. (1996). p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int. J. Cancer (Pred. Oncol.) 69: 190-192.
3. Bleiberg, H. (1996). Colorectal cancer: The challenge. Eur. J. Cancer 32A Supplememt 5: S2-S6.
4. Bracey, T.S., Miller, J.C., Preece, A. and Paraskeva, C. (1995). Gamma-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene 10: 2391-2396.
5. Brett, M.C., Pickard, M., Green, B., Howel-Evans, A., Smith, D., Kinsella, A. and Poston, G. (1996). p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur. J. Surg. Oncol. 22: 182-185.
6. Bunz, F., Hwang, P.M., Torrance, C, Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C, Kinzler, K.W. and Vogelstein, B. (1999). Disruption of p53 in human cancer cells alters the response to therapeutic agents. J. Clin. Invest. 104: 263-269.
7. Cascinu, S., Aschele, C, Barni, S., Debernardis, D., Baldo, C, Tunesi, G, Catalano, V., Staccioli, M.P., Brenna, A., Muretto, P. and Catalano, G. (1999). Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin. Cancer Res. 5: 1996-1999.
8. Cascinu, S., Catalano, V., Aschele, C, Bami, S., Debernardis, D., Gallo, L., Bandelloni, R., Staccioli, M.P., Baldelli, A.M., Brenna, A., Valenti, A., Muretto, P. and Catalano, G. (2000). Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Ann. Oncol. 11: 1053-1056.
9. Chu, E., Koeller, D., Johnston, P.G., Zinn, S. and Allegra, C.J. (1993). Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol. Pharmacol. 43: 527-533.
10. Corsi, D.C., Ciaparrone, M., Zannoni, G, Mancini, M., Cassano, A., Specchia, M., Pozzo, C, Martini, M. and Barone, C. (2002). Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur. J. Cancer 38: 527-534.
11. Dive, C. and Hickman, J.A. (1991). Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer 64: 192-196.
12. Fujii, M. (1999) Using preoperative UFT to predict sensitivity to fiuoropyrimidines in colorectal cancer. Oncology 13: 55-60.
13. Harris, C.C. (1996). Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88: 1442-1455.
14. Harwood, F. G., Frazier, M.W., Krajewski, S., Reed, J.C. and Houghton, J.A. (1996). Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells. Oncogene 12: 2057-2067.
15. Japanese Society for Cancer of the Colon and Rectum. (1997). Japanese Classification of Colorectal Carcinoma, 1st English ed. Kanehara Shuppan, Tokyo. Japan.
16. Johnston, P.G., Fisher, E.R., Rockette, H.E., Fisher, B., Wolmark, N., Drake, J.C., Chabner, B.A. and Allegra, C.J. (1994). The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol. 12: 2640-2647.
17. Johnston, P.G., Lenz, H-J., Leichman, CG, Danenberg, K.D., Allegra, C.J., Danenberg, P.V. and Leichman, L. (1995). Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55: 1407-1412.
18. Kamoshida, S., Matsuoka, H., Matsuyama, A., Shimomura, Y., Maruta, M. and Tsutsumi, Y. (2003). Reproducible and reliable immunohistochemical demonstration of thymidylate synthase in formalin-fixed, paraffin-embedded sections: Application of antigen retrieval in ethylenediaminetetraacetic acid solution. Acta Histochem. Cytochem. 36: 115-118.
19. Korsmeyer, S.J. (1999). BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 59: 1693s-1700s.
20. Kralovanszky, J., Koves, I., Orosz, Z., Katona, C, Toth, K., Rahoty, P., Czegledi, F., Kovacs, T., Budai, B., Hullan, L. and Jeney, A. (2002). Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors. Oncology 62: 167-174.
21. Leichman, CG, Lenz, H-J., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M. and Danenberg, P.V. (1997). Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15: 3223-3229.
22. Lenz, H-J., Danenberg, K.D., Leichman, C.G., Florentine, B., Johnston, P.G., Groshen, S., Zhou, L., Xiong, Y.P. Danenberg, P.V. and Leichiman, L.P. (1998). P53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin. Cancer Res. 4: 1227-1234.
23. Lenz H-J., Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R., Banerjee, D., Bertino, J.R., Groshen, S., Leichman L.P. and Leichman, CG. (1998). p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin. Cancer Res. 4: 1243-1250.
24. Leonard, C.J., Canman, C.E. and Kastan, M.B. (1995). The role of p53 in cell-cycle control and apoptosis: Implications for cancer. In: Important Advances in Oncology. Edited by DeVita, V, Hellman, S. and Rosenberg, S.A. J B Lippincott, Philadelphia, PA. USA. pp. 33-42.
25. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. and Jacks, T. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
26. Matsuura, T., Fukuda, Y., Fujitaka, T., Nishisaka, T., Sakatani, T. and Ito, H. (2000). Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma. Cancer 88: 1007-1015.
27. Maurer, CA., Friess, H., Bühler, S.S., Wahl, B.R., Graber, H., Zimmermann, A. and Büchler, M.W. (1998). Apoptosis inhibiting factor Bc1-Xl might be the crucial member of the Bcl-2 gene family in colorectal cancer. Digest. Dis. Sci. 43: 2641-2648.
28. Miller, R.T., Swanson, P.E. and Wick, M.R. (2000). Fixation and epitope retrieval in diagnostic immunohistochemistry: A concise review with practical considerations. Appl. Immunohistochem. Molec. Morphol. 8: 228-235.
29. Momand, J., Zambetti, G, Olson, D.C., George, D. and Levine, A.J. (1992). The p53 oncogene product forms a complex with the p53 protein and inhibits p53-mRNA transactivation. Cell 69: 1237-1245.
30. Nishimura, G, Terada, I., Kobayashi, T., Ninomiya, I., Kitagawa, H., Fushida, S., Fujimura, T., Kayahara, M., Shimizu, K., Ohta, T. and Miwa, K. (2002). Thymidine Phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol. Rep. 9: 479-482.
31. Nita, M.E., Nagawa, H., Tominaga, O., Tsuno, N., Fujii, S., Sasaki, S., Fu, C-G, Takenoue, T., Tsuruo, T. and Muto, T. (1998). 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br. J. Cancer 78: 986-992.
32. Nita, M.E., Ono-Nita, S.K., Tsuno, N., Tominaga, O., Takenoue, T, Sunami, E., Kitayama, J., Nakamura, Y. and Nagawa, H. (2000). BcI-Xl antisense sensitizes human colon cancer cell line to 5-fluorouracil. Jpn. J. Cancer Res. 91: 825-832.
33. Paradiso, A., Rabinovich, M., Vallejo, C, Machiavelli, M., Romero, A., Perez, J., Lacava, J., Cuevas, M.A., Rodriquez, R., Leone, B., Sapia, M.G., Simone, G. and de Lena, M. (1996). p53 and PCNA expression in advanced colorectal cancer: Response to chemotherapy and long-term prognosis. Int. J. Cancer 69: 437-441.
34. Paradiso, A., Simone, G., Petroni, S., Leone, B., Vallejo, C., Lacava, J., Romero, A., Machiavelli, M., de Lena, M., Allegra, C.J. and Johnston, P.G. (2000). Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br. J. Cancer 82: 560-567.
35. Pinedo, H.M. and Peters, G.F.J. (1988). Fluorouracil: Biochemistry and pharmacology. J. Clin. Oncol. 6: 1653-1664.
36. Rougier, R, Bugat, R., Douillard, J.Y., Culine, S., Suc, E., Brunet, R, Becouarn, Y, Ychou, M., Marty, M., Extra, J.M., Bonneterre, J., Adenis, A., Seitz, J.F., Ganem, G, Namer, M., Conroy, T., Negrier, S., Merrouche, Y, Burki, F., Mousseau, M., Herait, R and Mahjoubi, M. (1997). Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol. 15: 251-260.
37. Sakamoto, S., Tsukada, K., Sagara, T., Kawachi, Y, Murakami, S. and Iwama, T. (2002). Human colorectal malignancy and oral UFT. Anticancer Res. 22: 339-341.
38. Salonga, D., Danenberg, K.D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D.D., Lenz, H-J., Leichman, CG, Leichman, L., Diasio, R.B. and Danenberg, P.V. (2000). Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine Phosphorylase. Clin. Cancer Res. 6: 1322-1327.
39. Sobin, L.H. and Wittekind, C, editors. (1997). UICC: TNM Classification of Malignant Tumours, 5th ed. John Wiley, NY, USA.
40. Tomiak, A., Vincent, M., Earle, C.C., Johnston, P. G., Kocha, W., Taylor, M., Maroun, J., Eidus, L., Whinston, F. and Stitt, L (2001). Thymidylate synthase expression in stage II and III colon cancer. Am. J. Clin. Oncol. 24: 597-602.
41. Violette, S., Poulain, L., Dussaulx, E., Pepin, D., Faussat, A.M., Chambaz, J., Lacorte, J.M., Staedel, C. and Lesuffleur, T. (2002). Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int. J. Cancer 98: 498-504.
42. Yamachika, T., Nakanishi, H., Inada, K., Tsukamoto, T, Kato, T., Fukushima, M., Inoue, M. and Tatematsu, M. (1998). A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82: 70-77.
43. Zheng, M., Wang, H, Zhang, H., Ou, Q., Shen, B., Li, N. and Yu, B. (1999). The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells. J. Cancer Res. Clin. Oncol. 125: 357-360.